Literature DB >> 2586147

Low IL-1 beta production in leukemic cells from progressive B cell chronic leukemia (B-CLL).

M Aguilar-Santelises1, J F Amador, H Mellstedt, M Jondal.   

Abstract

In vitro production of IL-1 beta by cells from 32 patients with benign monoclonal lymphocytosis of undetermined significance (MLUS) and B cell chronic lymphocytic leukemia (B-CLL) was investigated. Normal B lymphocytes (2 x 10(6)) secreted approximately 5 ng/ml of IL-1 beta during 24 h and approximately ten times more after stimulation with Staphylococcus aureus, strain Cowan 1 (SAC). When patients were studied, a loss of IL-1 beta production was found in leukemic cells from progressive disease. Cells from MLUS patients secreted near normal levels of IL-1 beta and responded to SAC stimulation, whereas cells from patients with progressive B-CLL produced no, or little IL-1 beta, and did not respond to SAC. Loss of IL-1 beta production in progressively growing B-CLL may be related to an increased malignant character of these cells. This is discussed in relation to the immunogenicity of the leukemic cells and their capacity to differentiate.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2586147     DOI: 10.1016/0145-2126(89)90048-9

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

1.  Cytokine expression in B-CLL in relation to disease progression and in vitro activation.

Authors:  M Aguilar-Santelises; D Gigliotti; L M Osorio; A D Santiago; H Mellstedt; M Jondal
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

2.  Expression of interleukin-1 alpha, interleukin-1 beta and interleukin-6 in chronic B lymphocytic leukaemia (B-CLL) cells from patients at different stages of disease progression.

Authors:  M Aguilar-Santelises; R Magnusson; S B Svenson; A Loftenius; B Andersson; H Mellstedt; M Jondal
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

3.  Activated CLL cells regulate IL-17F-producing Th17 cells in miR155-dependent and outcome-specific manners.

Authors:  Byeongho Jung; Gerardo Ferrer; Pui Yan Chiu; Rukhsana Aslam; Anita Ng; Florencia Palacios; Michael Wysota; Martina Cardillo; Jonathan E Kolitz; Steven L Allen; Jacqueline C Barrientos; Kanti R Rai; Nicholas Chiorazzi; Barbara Sherry
Journal:  JCI Insight       Date:  2022-06-22

4.  Presence of clonal T cell populations in chronic B lymphocytic leukemia and smoldering myeloma.

Authors:  T Wen; H Mellstedt; M Jondal
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.